, Volume 53, Issue 10, pp 2112–2119 | Cite as

The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

  • M. D. WithamEmail author
  • F. J. Dove
  • M. Dryburgh
  • J. A. Sugden
  • A. D. Morris
  • A. D. Struthers



Low 25-hydroxyvitamin D levels predict future cardiovascular events and are common in patients with type 2 diabetes. We compared the effect of 100,000 and 200,000 IU doses of vitamin D3 on endothelial function, blood pressure and markers of glycaemic control in patients with type 2 diabetes.


This was a randomised, parallel group, placebo-controlled trial. Patients with type 2 diabetes and baseline 25-hydroxyvitamin D levels <100 nmol/l were enrolled from community and hospital-based diabetes clinics. Participants were assessed in a university department of clinical pharmacology and received a single oral dose of placebo or vitamin D3 (100,000 IU or 200,000 IU) at baseline, randomly allocated via numbered bottles prepared offsite; participants and investigators were both blinded to treatment allocation. Endothelial function, office blood pressure, B-type natriuretic peptide, insulin resistance and glycosylated haemoglobin were measured at baseline, and at 8 and 16 weeks.


We randomised 61 participants to the three groups (placebo 22, 100,000 IU vitamin D3 19, 200,000 IU vitamin D3 20). There was no significant difference in the primary outcome of endothelial function at 8 weeks (placebo 5.2%, n = 22; 100,000 IU 4.3%, n = 19; 200,000 IU 4.9%, n = 17) or at 16 weeks. Insulin resistance and glycosylated haemoglobin did not improve with either dose of vitamin D3. On covariate analysis, systolic blood pressure was significantly lower in both treatment arms than in the placebo group at 8 weeks (placebo 146.4 mmHg, 100,000 IU 141.4 mmHg [p = 0.04 vs placebo], 200,000 IU 136.8 mmHg [p = 0.03 vs placebo]). B-type natriuretic peptide levels were significantly lower in the 200,000 IU group by 16 weeks (placebo 34 pg/ml, 200,000 IU 21 pg/ml, p = 0.02). No significant excess of adverse effects was noted in the treatment arms.


High-dose vitamin D3 improved systolic blood pressure and B-type natriuretic peptide levels, but not endothelial function, insulin resistance or glycosylated haemoglobin in patients with type 2 diabetes.

Trial registration

ISRCTN50587697 (


Diabetes UK, grant number 06/0003429. M. D. Witham is funded by a Scottish Government NES/CSO Clinician Scientist Award.


Blood pressure Diabetes mellitus Endothelial function Randomised controlled trial Vitamin D 



Analysis of covariance


B-type natriuretic peptide


Flow-mediated dilatation


25-Hydroxyvitamin D


A substantial body of observational evidence now links low vitamin D levels with type 2 diabetes mellitus. Low vitamin D levels are common in patients with type 2 diabetes [1], over 50% of whom have a serum 25 hydroxyvitamin D (25OHD) level of <50 nmol/l [2, 3]. Low vitamin D levels are associated with a higher risk of developing type 2 diabetes [4], worse glycaemic control in type 2 diabetes, higher serum lipid levels and a higher prevalence of cardiovascular disease [3]. Low vitamin D levels are also associated with an increased risk of hypertension and cardiovascular events in population-based studies [5, 6, 7, 8].

Data on the effects of vitamin D supplementation in patients with type 2 diabetes are less clear-cut. A number of small studies failed to show any improvement in glycaemic control or indices of insulin sensitivity during supplementation [2, 9, 10], although supplementation in patients with impaired glucose tolerance but without frank diabetes did successfully improve insulin resistance in two trials [10, 11].

Our previous work [2] has shown that a single large dose of vitamin D2 (100,000 IU orally) improved blood pressure and endothelial function (a key surrogate marker of cardiovascular risk) at 8 weeks post dose in patients with type 2 diabetes and baseline 25OHD levels below 50 nmol/l. The positive effects of vitamin D supplementation on endothelial function have since been confirmed in a non-diabetic population [12]. Endothelial function is an important surrogate marker for future cardiovascular events; almost all interventions that reduce cardiovascular events also improve endothelial function, although some that improve endothelial function (e.g. hormone replacement therapy) do not reduce cardiovascular events because of adverse effects on other biological systems [13].

Despite these promising findings, the optimum dose of vitamin D to produce beneficial effects on the cardiovascular system is unclear. The question therefore arises as to whether a larger dose of vitamin D would produce greater improvement in surrogate markers of cardiovascular disease and might also improve measures of glycaemic control, which was unchanged in our previous study. Our previous work was on patients with 25OHD levels below 50 nmol/l. For optimum health, levels of 25OHD above 75 nmol have been postulated to be necessary [14]. Thus we also tested whether patients with higher baseline 25OHD levels might benefit from vitamin D supplementation.



We performed a randomised, placebo-controlled, double-blind parallel-group trial. Participants aged 18 years and over with a diagnosis of type 2 diabetes mellitus according to the World Health Organization were recruited from primary care and secondary care diabetes clinics by the attending clinician assisted by the study research nurse. Patients were excluded if they were already taking vitamin D supplements and had: a serum 25OHD level of >100 nmol/l; serum creatinine >200 μmol/l; liver function tests (alanine aminotransferase, bilirubin, alkaline phosphatase) >3 times the upper limit of the local reference range; albumin-adjusted calcium >2.55 mmol/l or <2.15 mmol/l; and a history of sarcoidosis, renal calculi or metastatic malignancy. Patients unable to give written informed consent were excluded, as were women of childbearing potential who were pregnant, lactating or not undertaking effective contraceptive measures. Each participant was enrolled for 16 weeks. Ethical approval was obtained from Tayside Research Ethics Committee (number 07/S1401/101). Written informed consent was obtained from all participants and the study was conducted according to the principles of the Declaration of Helsinki.

Randomisation and blinding

Participants were randomised to one of three parallel groups: (1) placebo; (2) vitamin D3 100,000 IU; and (3) vitamin D3 200,000 IU. Medication (Vigantol oil, 20,000 IU vitamin D3/ml) and placebo (Miglyol oil) were provided by Merck, Darmstadt, Germany, and were bottled and labelled by Tayside Pharmaceuticals, Dundee, UK. Tayside Pharmaceuticals prepared a computer-generated randomisation code stored in sealed envelopes until the end of the study. Each participant was given the next numbered medication bottle in sequence to preserve allocation concealment. Participants ingested the medication in the presence of the researchers to ensure 100% adherence. The participants and the research team remained blinded to treatment allocation until after the main analyses were completed.

Outcome measures

Outcome measures were performed at baseline (immediately prior to dosing), and at 8 and 16 weeks.

Primary outcome

Endothelial function was assessed by measuring flow-mediated dilatation (FMD) of the brachial artery in response to hyperaemia (endothelium-dependent vasodilation) [15]. An ultrasound machine (Sequoia 512; Siemens, Camberley, UK) with 8 MHz linear array probe was used. Brachial artery diameter and flow were determined by M-mode and Doppler ultrasound; diameter was measured using Vascular Research Tools software (Medical Imaging Applications LLC, Coralville, IA, USA). The mean diameter was measured during baseline acquisition and compared with the maximum diameter achieved in the 2 min after cuff deflation. FMD was expressed as the percentage change from baseline diameter. The change in FMD between baseline and 8 weeks was assessed as the primary outcome.

Secondary outcomes

Office blood pressure measurements were taken using an oscillometric system (HEM-705CP; Omron, Henfield, UK). Measurements were taken after 10 min in the supine position. The mean of the second and third readings was recorded. Fasting (minimum 6 h fast) venous blood was drawn after 10 min in the seated position for measurement of B-type natriuretic peptide (BNP), renin, aldosterone, calcium, albumin, parathyroid hormone, insulin, glucose, HbA1c and 25OHD. Serum 25OHD was measured by ELISA (IDS, Boldon, UK). The interassay coefficient of variation was 12%. BNP samples were collected into chilled aprotinin bottles, spun for 10 min at 1,137 g and stored at −70°C. BNP was measured in batches using a radioimmunoassay (Bachem, St Helens, UK). Intra-assay coefficient of variation was 12.5%. Renin and aldosterone were spun for 10 min at 1,137 g and the supernatant fraction was stored at −20°C prior to batched analysis using radioimmunoassay kits (Diasorin, Bracknell, UK). The intra-assay coefficients of variation were 4% and 6%, respectively. Fasting insulin and glucose measurements were used to calculate HOMA [16] using the formula: fasting glucose (mmol/l) × fasting insulin (pmol/l)/156.

Baseline data on comorbid disease, medication, height and weight were collected. Daily dietary calcium intake was ascertained using a food questionnaire analysed using values derived from McCance and Widdowson’s Composition of Foods dataset [17]. All adverse events, including hospital admission, morbidity and death were recorded.

Statistical analyses and sample size calculations

Data were analysed using SPSS 15.0 (SPSS, Chicago, IL, USA). Each active group was compared with placebo separately. Similarly, each follow-up time point was analysed separately, as the effect of vitamin D was anticipated to vary non-predictably over time. Differences between groups were compared using analysis of covariance (ANCOVA), with baseline values of 25OHD and the outcome under study as covariates. For FMD and BNP analyses, baseline systolic blood pressure was included as an additional covariate. Values for BNP were not normally distributed and were therefore log-transformed prior to ANCOVA testing. Analyses were by intention to treat with the exception that participants who were unable to attend a follow-up visit were omitted from analysis for that time point only. Imputation was not performed to account for these missing values, as data were not missing at random; no adjustment was made for multiple testing.

The study was powered to detect a 2% absolute difference in FMD between the placebo and 100,000 IU groups at 8 weeks. Exercise training and statin therapy (which are known to reduce the risk of cardiovascular events) have been shown to produce an improvement of at least 2% in brachial artery FMD [18, 19]. To detect this change with 80% power, assuming a standard deviation of change of 3% as found in our previous work [2] and alpha = 0.05, requires 27 participants per group. We therefore aimed to recruit 90 patients (30 per group) to allow for 10% dropout over the course of the study.


We screened 70 participants for inclusion in the study. Of these 70, 68 (97%) had baseline 25OHD levels <100 nmol/l; 64 of 70 (91%) had levels <75 nmol/l and 49 of 70 (70%) had levels <50 nmol/l. A total of 61 participants were randomised, of whom 58 (95%) attended the 8 week and 16 week follow-up visits. Figure 1 depicts participant flow through the study.
Fig. 1

Participant flow chart

Baseline details are given in Table 1. No substantial between-group differences in baseline values were noted. Levels of statin use and renin–angiotensin system blocking drugs were high in all groups. All groups had baseline mean systolic blood pressures above target range for type 2 diabetes. Three patients changed antihypertensive medications between baseline and 8 weeks (one increased ACE inhibitor dose in the placebo group, one decreased ACE inhibitor dose in the placebo group and one started diltiazem in the 100,000 IU group). A further three patients changed antihypertensive medications between 8 weeks and 16 weeks (one started furosemide in the 100,000 IU group, one increased lisinopril dose in the placebo group and one stopped indoramin and commenced dexamethasone in the placebo group).
Table 1

Baseline participant characteristics




100,000 IU

200,000 IU





Mean age (years)

66.7 (9.7)

65.3 (11.1)

63.3 (9.6)

Male sex, n (%)

12 (55)

16 (84)

13 (65)

On statins, n (%)

17 (77)

17 (89)

14 (70)

On ACE inhibitors or ARB, n (%)

17 (77)

17 (89)

13 (65)

History of ischaemic heart disease, n (%)

5 (23)

6 (32)

6 (30)

History of hypertension, n (%)

19 (86)

13 (68)

14 (70)

Taking insulin, n (%)

5 (23)

4 (21)

5 (25)

Baseline systolic BP (mmHg)

143.9 (24.4)

149.6 (24.0)

145.1 (25.0)

Baseline diastolic BP (mmHg)

80.3 (9.7)

81.7 (12.4)

80.7 (14.3)

BMI (kg/m2)

33.3 (7.1)

31.1 (6.7)

29.7 (4.2)

Baseline 25OHD (nmol/l)

45 (17)

41 (14)

48 (21)

HbA1c (%)

7.8 (1.3)

7.0 (1.6)

6.9 (0.8)


13.0 (9.7)

11.7 (12.7)

12.0 (14.5)

Total cholesterol (mmol/l)

3.66 (0.71)

4.09 (1.14)

4.07 (0.97)

PTH (pmol/l)

4.8 (3.4)

4.5 (1.8)

4.4 (1.9)

Adjusted calcium (mmol/l)

2.34 (0.08)

2.32 (0.07)

2.34 (0.09)

Calcium intake (mmol/day)

12.4 (5.2)

16.0 (7.2)

13.2 (6.2)

Baseline FMD (%)

5.4 (2.7)

5.1 (3.0)

6.4 (3.2)

Baseline median BNP (pg/ml)a

17 (40)

30 (166)

21 (45)

Baseline median renin (pmol/l)a

19.0 (146.9)

26.1 (80.6)

47.4 (109.0)

Baseline median aldosterone (pmol/l)a

216 (116)

169 (191)

180 (274)

Values are mean (SD) or amedian (interquartile range)

ARB, angiotensin receptor blocker; HOMA IR, HOMA of insulin resistance; PTH, parathyroid hormone

Tables 2 and 3 show the outcome measures at 8 and 16 weeks, respectively. Despite increases in 25OHD levels in both supplemented groups, endothelial function as measured using FMD did not differ significantly between groups at 8 or 16 weeks. After adjustment, between-group differences in FMD change at 8 weeks remained non-significant (placebo vs 100,000 IU −1.0% [95% CI −2.9, 0.9], placebo vs 200,000 IU −0.3% [95% CI −2.3, 1.8]). Change between baseline and 16 weeks was also non-significant (placebo vs 100,000 IU 0.2% [95% CI −1.2, 1.5], placebo vs 200,000 IU 1.3% [95% CI −0.1, 2.7]).
Table 2

Main outcome measures at 8 weeks



p valueb

p valuec


100,000 IU

200,000 IU






FMD (%)

5.2 (3.1)

4.3 (2.3)

4.9 (3.2)



Systolic BP (mmHg)

146.4 (19.5)

141.4 (16.6)

136.8 (12.9)



Diastolic BP (mmHg)

78.9 (9.2)

77.1 (11.7)

74.4 (9.8)



Median BNP (pg/ml)a

31 (78)

25 (50)

25 (33)



HbA1c (%)

7.6 (1.3)

7.1 (2.0)

7.0 (0.7)




25.3 (33.6)

13.5 (12.8)

11.9 (10.4)



Cholesterol (mmol/l)

3.77 (0.75)

3.90 (1.00)

3.69 (0.71)



25OHD (nmol/l)

54 (20)

63 (20)

79 (31)



PTH (pmol/l)

4.7 (3.6)

4.0 (1.5)

4.6 (2.4)



Adjusted calcium (mmol/l)

2.33 (0.07)

2.33 (0.08)

2.31 (0.08)



Values are mean (SD) or amedian (interquartile range)

bPlacebo vs 100,000 IU; cplacebo vs 200,000 IU

HOMA IR, HOMA of insulin resistance; PTH, parathyroid hormone

Table 3

Main outcome measures at 16 weeks



p valueb

p valuec


100,000 IU

200,000 IU






FMD (%)

5.1 (1.8)

5.2 (2.1)

6.5 (2.6)



Systolic BP (mmHg)

143.4 (16.4)

144.6 (20.4)

139.5 (15.4)



Diastolic BP (mmHg)

78.4 (10.3)

79.6 (11.9)

77.6 (11.7)



Median BNP (pg/ml)a

34 (59)

25 (52)

21 (35)



HbA1c (%)

7.5 (1.4)

6.9 (1.5)

6.7 (0.9)




17.2 (19.3)

15.9 (14.3)

10.5 (7.2)



Cholesterol (mmol/l)

3.83 (0.89)

3.88 (0.92)

3.94 (0.77)



25OHD (nmol/l)

53 (20)

59 (18)

76 (30)



PTH (pmol/l)

4.7 (3.2)

4.1 (2.0)

3.9 (1.7)



Adjusted calcium (mmol/l)

2.32 (0.07)

2.34 (0.07)

2.31 (0.09)



Values are mean (SD) or amedian (interquartile range)

bPlacebo vs 100,000 IU; cplacebo vs 200,000 IU

HOMA IR, HOMA of insulin resistance; PTH, parathyroid hormone

Systolic blood pressure fell significantly between baseline and 8 weeks in both treatment groups compared with placebo (placebo vs 100,000 IU −8.2 mmHg [95% CI −16.2, −0.2], placebo vs 200,000 IU −9.3 mmHg [95% CI −17.5, −1.1]), but no significant differences in diastolic blood pressure were seen between baseline and 8 weeks (placebo vs 100,000 IU −2.5 mmHg [95% CI −7.6, 2.5], placebo vs 200,000 IU −3.2 mmHg [95% CI −8.4, 2.0]). By 16 weeks, BNP levels fell significantly in the 200,000 IU group compared with placebo.

The changes in blood pressure were not mirrored by changes in renin or aldosterone levels; there was no significant change in renin levels at 8 weeks compared with baseline (37.9 vs 7.1 pmol/l/ for 100,000 IU vs placebo, p = 0.28; −54.5 vs 7.1 pmol/l/ for 200,000 IU vs placebo, p = 0.07). Similarly, aldosterone levels did not change significantly at 8 weeks compared with baseline (119 vs 39 pmol/l for 100,000 IU vs placebo, p = 0.31; −19 vs 39 pg/ml for 200,000 IU vs placebo, p = 0.28). Glycaemic control as measured by HbA1c did not change in any group, and insulin resistance as measured by HOMA did not improve significantly in the supplementation groups compared with placebo.

No excess of side-effects was seen in either of the vitamin D groups; in particular, no participant developed hypercalcaemia (adjusted calcium >2.60 mmol/l) during the study. Four adverse events were recorded in the placebo group (diarrhoea, decompensated heart failure, hyperkalaemia, death from myocardial infarction), five in the 100,000 IU group (two urinary tract infections, two respiratory tract infections, one diarrhoea) and one case of asymptomatic bradycardia was noted in the 200,000 IU group.


Key findings

Neither dose of vitamin D in this study significantly improved endothelial function as measured by FMD, relative to placebo, although a modest improvement in FMD was seen at 16 weeks in the 200,000 IU group. After adjustment for baseline differences, both doses of vitamin D3 caused a statistically and clinically significant fall in systolic blood pressure, but not diastolic blood pressure. Although the 200,000 IU dose of vitamin D3 caused a larger increase in 25OHD levels, the magnitude of the blood pressure change was similar in both the 100,000 and 200,000 IU treatment arms. The effect of the single large dose of vitamin D on 25OHD levels persisted at 16 weeks, but the effect on blood pressure was attenuated at this time point. BNP, a powerful surrogate marker of cardiovascular risk, fell significantly by 16 weeks in the 200,000 IU intervention group. No significant effect of vitamin D supplementation on HbA1c or insulin resistance, even at the higher dose of vitamin D, was evident.

Strengths and weaknesses

Strengths of our study include the double-blind randomised controlled design, 100% adherence to study medication and the measurement of a range of vascular and glycaemic indices. Participants in this study were receiving high levels of statins and ACE inhibitors at baseline, suggesting that they were representative of current standards of care. Furthermore, we enrolled participants with a wide range of baseline 25OHD levels, enhancing the generalisability of our findings. The study did not achieve its recruitment goal due to staff illness and subsequent time constraints within the study, but the minimum clinically important threshold of 2% improvement in FMD lies outside the 95% confidence limits at 8 weeks and is only just within the confidence limits at 16 weeks. It is therefore unlikely that low patient numbers explain the lack of effect of vitamin D supplementation on the primary outcome of FMD. The wide confidence intervals do not, however, exclude a potentially deleterious effect on FMD at 8 weeks, nor do they encompass a deterioration of 2% at 16 weeks for either treatment group. The confidence intervals surrounding change in blood pressure values are wide due to the small size of the study, and larger studies will be needed to give a more precise estimate of effect on blood pressure reduction.

Findings in relation to other studies

The magnitude of the fall in systolic blood pressure was similar to that seen in our previous study [2]. Our findings are also consistent with a recently published meta-analysis [20], which reported a small reduction in blood pressure with vitamin D therapy, but only in studies with a mean baseline systolic blood pressure of >140 mmHg. We were unable to confirm our previous finding of improved endothelial function with vitamin D supplementation, although such an improvement subsequent to vitamin D administration has also been seen in participants without type 2 diabetes mellitus [12]. Although small study numbers limited the statistical power of our study to demonstrate a difference in FMD, it is less clear why the magnitude of the effect was smaller than that observed in our previous study; participants had similarly impaired endothelial function in both studies, and had similar blood pressure and baseline 25OHD levels. Although the mechanisms by which vitamin D may affect vascular health are not well elucidated [21], more patients in the current study were taking statins and ACE inhibitors at baseline; vitamin D can block renin production in animal models [22] and has been postulated to have actions similar to statins [23], perhaps by inhibiting uptake of cholesterol by macrophages and reducing foam cell formation [24]. Thus the mechanisms by which vitamin D improves endothelial function may have already been actuated by other medications; indeed cholesterol levels were well controlled and neither renin or aldosterone levels changed significantly with vitamin D supplementation in the current study. This finding also argues against the possibility that reduced renin levels drove the fall in blood pressure observed in this study.

Several studies have demonstrated that vitamin D can improve insulin resistance in patients with prediabetic states including insulin resistance and impaired glucose tolerance [10, 11, 25, 26]. However, studies examining the effect of vitamin D on insulin resistance and glycaemic control in patients with established type 2 diabetes have been negative [9, 10], and the large Women’s Health Initiative study [27] found no reduction in new diagnoses of diabetes in participants receiving calcium plus a small (400 IU per day) dose of vitamin D3. Similarly, a post hoc analysis of the large MRC RECORD trial of calcium and vitamin D supplementation showed no reduction in self-reported new-onset diabetes or new-onset use of insulin or hypoglycaemic medication, despite the vitamin D dose in this trial being 800 IU per day [28].

Left ventricular hypertrophy is known to be common in patients with type 2 diabetes and is reflected by elevated levels of BNP [29]. BNP is also associated with silent myocardial ischaemia in patients with type 2 diabetes mellitus [30] and an inverse association exists between 25OHD levels and BNP levels in heart failure patients [31] and in patients referred for coronary angiography [32]. Reductions in BNP levels subsequent to vitamin D supplementation could therefore be due to reductions in blood pressure with consequent beneficial effects on left ventricular remodelling; they could also be due to anti-ischaemic effects on the myocardium. The effects on BNP are unlikely to be a chance finding; similar effects were seen with vitamin D supplementation in a trial of older patients with chronic heart failure due to left ventricular systolic dysfunction [33]. BNP is known to be a significant predictor of future cardiovascular and all-cause mortality in patients with type 2 diabetes [34]; thus interventions that improve this marker could potentially confer prognostic benefits.

Future work

This study, combined with our previous meta-analysis of vitamin D studies, suggests that hypertensive patients may benefit from vitamin D intervention. The magnitude of blood pressure reduction in our two diabetes studies was consistent, suggesting that hypertensive patients with type 2 diabetes would be a good target for larger trials of vitamin D therapy, focussing on whether vitamin D can reduce cardiovascular events and cardiovascular deaths. Further work is also needed to test the effect of longer-term, repeated dosing of vitamin D and to establish whether still larger doses of vitamin D are required to produce useful improvement in glycaemic control.



Our thanks go to all the participants, to L. MacFarlane (University of Dundee) for laboratory analyses and to R. Price (University of Dundee) for assistance with the dietary questionnaire. Thanks also to Merck for providing vitamin D and placebo oil. The study was funded by Diabetes UK, grant number 06/0003429. M. D. Witham is funded by a Scottish Government NES/CSO Clinician Scientist Award.

Duality of interest

J. A. Sugden, M. D. Witham, A. D. Morris and A. D. Struthers currently or have previously received grant funding from Diabetes UK, Chest Heart and Stroke Scotland, Chief Scientist Office, Scottish Government, Heart Research UK and ME Research UK to support research into the cardiovascular effects of vitamin D.


  1. 1.
    Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E (1995) Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 27:181–188CrossRefPubMedGoogle Scholar
  2. 2.
    Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320–325CrossRefPubMedGoogle Scholar
  3. 3.
    Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G (2006) Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29:722–724CrossRefPubMedGoogle Scholar
  4. 4.
    Pittas AG, Dawson-Hughes B, Li T et al (2006) Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29:650–656CrossRefPubMedGoogle Scholar
  5. 5.
    Forman JP, Giovannucci E, Holmes MD et al (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063–1069CrossRefPubMedGoogle Scholar
  6. 6.
    Dobnig H, Pilz S, Scharnagl H et al (2008) Independent association of low serum 25-hydroxyvitamin d and 1, 25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349CrossRefPubMedGoogle Scholar
  7. 7.
    Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–511CrossRefPubMedGoogle Scholar
  8. 8.
    Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168:1174–1180CrossRefPubMedGoogle Scholar
  9. 9.
    Jorde R, Figenschau Y (2009) Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 48:349–354CrossRefPubMedGoogle Scholar
  10. 10.
    Pittas AG, Harris SS, Stark PC, Dawson-Hughes B (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30:980–986CrossRefPubMedGoogle Scholar
  11. 11.
    von Hurst PR, Stonehouse W, Coad J (2010) Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—a randomised, placebo-controlled trial. Br J Nutr 103:549–555CrossRefGoogle Scholar
  12. 12.
    Tarcin O, Yavuz DG, Ozben B et al (2009) Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 94:4023–4030CrossRefPubMedGoogle Scholar
  13. 13.
    Widlansky ME, Gokce N, Keaney JF, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149–1160CrossRefPubMedGoogle Scholar
  14. 14.
    Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28PubMedGoogle Scholar
  15. 15.
    Corretti MC, Anderson TJ, Benjamin EJ et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265CrossRefPubMedGoogle Scholar
  16. 16.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMedGoogle Scholar
  17. 17.
    Food Standards Agency (2002) McCance and Widdowson's The Composition of Foods, 6th summary edition. Royal Society of Chemistry, CambridgeGoogle Scholar
  18. 18.
    Koh KK, Quon MJ, Han SH et al (2008) Simvastatin improves flow-mediated dilatation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31:776–782CrossRefPubMedGoogle Scholar
  19. 19.
    Vona M, Rossi A, Capodaglio P et al (2004) Impact of physical training and detraining on endothelium-dependent vasodilatation in patients with recent acute myocardial infarction. Am Heart J 147:1039–1046CrossRefPubMedGoogle Scholar
  20. 20.
    Witham MD, Nadir MA, Struthers AD (2009) Effect of vitamin D on blood pressure—a systematic review and meta-analysis. J Hypertens 27:1948–1954CrossRefPubMedGoogle Scholar
  21. 21.
    Pilz S, Tomaschitz A, Ritz E, Pieber TR (2009) Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 6:621–630CrossRefPubMedGoogle Scholar
  22. 22.
    Sigmund CD (2002) Regulation of renin expression and blood pressure by vitamin D(3). J Clin Invest 110:155–156PubMedGoogle Scholar
  23. 23.
    Grimes DS (2006) Are statins analogues of vitamin D? Lancet 368:83–86CrossRefPubMedGoogle Scholar
  24. 24.
    Oh J, Weng S, Felton SK et al (2009) 1, 25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 120:687–698CrossRefPubMedGoogle Scholar
  25. 25.
    Mak RH (1998) 1, 25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353–1357CrossRefPubMedGoogle Scholar
  26. 26.
    Allegra V, Luisetto G, Mengozzi G, Martimbianco L, Vasile A (1994) Glucose-induced insulin secretion in uremia: role of 1 alpha, 25(HO)2-vitamin D3. Nephron 68:41–47CrossRefPubMedGoogle Scholar
  27. 27.
    de Boer IH, Tinker LF, Connelly S et al (2008) Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 31:701–707CrossRefPubMedGoogle Scholar
  28. 28.
    Avenell A, Cook JA, Maclennan GS, McPherson GC (2009) Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 38:606–609CrossRefPubMedGoogle Scholar
  29. 29.
    Dawson A, Davies JI, Morris AD, Struthers AD (2005) B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am J Hypertens 18:1586–1591CrossRefPubMedGoogle Scholar
  30. 30.
    Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD (2006) B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 92:916–920CrossRefPubMedGoogle Scholar
  31. 31.
    Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P (2003) Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 41:105–112CrossRefPubMedGoogle Scholar
  32. 32.
    Pilz S, Marz W, Wellnitz B et al (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93:3927–3935CrossRefPubMedGoogle Scholar
  33. 33.
    Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME (2010) The effects of vitamin D supplementation on physical function and quality of life in older heart failure patients: a randomised controlled trial. Circ Heart Fail 3:195–201CrossRefPubMedGoogle Scholar
  34. 34.
    Bhalla MA, Chiang A, Epshteyn VA et al (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44:1047–1052CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • M. D. Witham
    • 1
    Email author
  • F. J. Dove
    • 1
  • M. Dryburgh
    • 1
  • J. A. Sugden
    • 1
  • A. D. Morris
    • 2
  • A. D. Struthers
    • 3
  1. 1.Ageing and HealthNinewells HospitalDundeeUK
  2. 2.Department of Diabetic MedicineUniversity of DundeeDundeeUK
  3. 3.Department of Clinical PharmacologyUniversity of DundeeDundeeUK

Personalised recommendations